CL2008002660A1 -
Substituted quinoline derived compounds, serotonin 5-ht6 receptor inhibitors; pharmaceutical composition; and its use in the treatment of disorders of the central nervous system, such as Alzheimer's, schizophrenia and obesity.
- Google Patents
Substituted quinoline derived compounds, serotonin 5-ht6 receptor inhibitors; pharmaceutical composition; and its use in the treatment of disorders of the central nervous system, such as Alzheimer's, schizophrenia and obesity.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=68424536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002660(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co KgfiledCriticalAbbott Gmbh & Co Kg
Publication of CL2008002660A1publicationCriticalpatent/CL2008002660A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Compuestos derivados de quinolina, composición farmacéutica, útil para tratar un trastorno seleccionado de enfermedades del sistema nervioso central, enfermedades de adicción u obesidad.Quinoline derived compounds, pharmaceutical composition, useful for treating a selected disorder of diseases of the central nervous system, addiction diseases, or obesity.
CL2008002660A2008-03-202008-09-08
Substituted quinoline derived compounds, serotonin 5-ht6 receptor inhibitors; pharmaceutical composition; and its use in the treatment of disorders of the central nervous system, such as Alzheimer's, schizophrenia and obesity.
CL2008002660A1
(en)
Substituted quinoline derived compounds, serotonin 5-ht6 receptor inhibitors; pharmaceutical composition; and its use in the treatment of disorders of the central nervous system, such as Alzheimer's, schizophrenia and obesity.
2-amino-quinoline derived compounds, antagonists of the serotonin 5-ht 5a receptor; preparation process, pharmaceutical composition; and use of the compounds in the prevention or treatment of depression, anxiety disorders, schizophrenia, panic disorders, memory disorders, dementia, among others.
Compounds derived from 1,3-disubstituted-4-phenyl-1h-pyridin-2-one, allosteric modulators of the glutamatergic receptor mglur2; Pharmaceutical composition and use of the compounds in the treatment of neurological and psychiatric conditions mediated by mglur2.
Compounds derived from quinuclidine, acetylcholine a7 receptor ligands; its pharmaceutical composition; its use for the treatment of disorders of the central nervous system, especially affective and neurodegenerative diseases such as schizophrenia and Alzheimer's.
Compounds derived from 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta [a] naphthalenes, phosphodiestearase 2 and / or 10 inhibitors; pharmaceutical composition; and its use for prevention or treatment of diseases of the nervous system, such as cognitive deficiency, dementia, anxiety disorders, enf. from Alzheimer, enf. from parkinson, others
Heterocyclic compounds derived from substituted pyridine carboxamide; Preparation process; pharmaceutical composition; pharmaceutical combination; use in the treatment of cell proliferative disorders, parkinson's disease, cancer, among others.
Substituted benzoazepine derived compounds; intermediate compounds; synthesis method; pharmaceutical composition; and use in the treatment or prevention of a central nervous system disorder.
Compounds derived from n-phenyl- (piperazinyl or homopiperazinyl) -benzenesulfonamide or benzenesulfonyl-phenyl- (piperazine or homopiperazine), 5-ht6 serotonin receptor modulators; pharmaceutical composition; and its use for the treatment for the treatment of diseases of the central nervous system, of addiction or obesity.
Triazolo derivative compounds, pde10 inhibitors; preparation procedure; use for the treatment and / or prophylaxis of psychotic disorders, schizophrenia, anxiety, drug addiction, parkinson's disease, among others.
Crystalline form of hydrochloride of (s) - (2- (6-chloro-7-methyl-1h-benzo [d] imidazol-2-yl) -2-methylpyrrolidin-1-yl) (5-methoxy-2- ( 2h-1,2,3-triazol-2-yl) phenyl) methanone; pharmaceutical composition comprising it; and its use for the treatment or prevention of sleep disorders, such as dysomnias, parasomnias, among others.
Crystalline form anhydrous orvepitant maleate; pharmaceutical composition; and its use to treat disorders of the central nervous system, such as depression, anxiety, post-traumatic stress disorders, emesis, and / or sleep disorders.